Selinexor in Combination With Chidamide in Unfit Relapsed/Refractory Acute Leukemia: a Phase 2, Single-Arm, Open-Label, Multi-Center Prospective Study.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Number of Participants With ORR
研究概览
简要总结
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor combined with chidamide in the treatment of unfit R/R AML.
详细描述
This protocol corresponds to a multicenter, open-label, single arm, prospective study designed to determine the efficacy and safety of selinexor in combination with chidamide for unfit R/R AML.
Selinexor will be given orally at 40 or 60mg on d1,4,8,11; Chidamide will be given orally at 10mg on d1-28; 28 days per cycle. patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive treatment until disease progression or unacceptable toxic effects. After completion of study treatment, participants are followed up every 3 to 6 months for up to 2 years.
Study design allows 42 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged 18 to 75 years old.
- •Diagnosis of relapsed or refractory AML (defined according to the the World Health Organization [WHO] 2016 criteria) of any type except for acute promyelocytic leukemia (APL; AML M3).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 2-
- •Patients whose expecting survival time will be more than 3 months.
- •One of the serious heart, lung, liver, kidney disease:
- •Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction <= 50% or chronic stable angina;
- •Diffusing capacity of the Lung for Carbon Monoxide (DLCO) <= 65% or Forced Expiratory Volume in 1 second (FEV1) <= 65%;
- •Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × Upper Limit of Normal (ULN);
- •Creatinine clearance >= 30 mL/min to < 45 ml/min;
- •Other comorbidities that the physician judges to be incompatible with intensive chemotherapy.
- •Patients who had not received radiotherapy, chemotherapy, targeted therapy within one week before enrollment.
- •Fertile women and men whose partner is of childbearing potential or pregnant should agree to practice complete abstinence or to use a condom during therapy and dose interruptions and for 90 days after the last treatment.
- •Patients who are suitable for intensive chemotherapy but refuse it.
- •Patients who have known and voluntarily signed the informed consent (ICF).
排除标准
- •History of any malignancies prior to study entry with exception noted in the protocol.
- •Patients who had previously been treated with selinexor and/or chidamide.
- •Patients with APL/AML M3, or t(9;22)(q34.1;q11.2); BCR-ABL1 positive AML.
- •Absolute white blood cell count >=100*10^9/L.
- •Persistent toxicity due to previous chemotherapy or radiotherapy did not recover to 2 grade.
- •Presence of CNS leukemia.
- •Patients who had undergone cardiac angioplasty or stent implantation within 12 months before signing the informed consent form, or had myocardial infarction or instability history of defined angina or other clinically significant cardiac events.
- •Ucontrolled active infection (including bacterial, fungal or viral infections) and bleeding from internal organs.
- •Pregnant and lactating women.
- •Participated in any other clinical trials within 3 months before signing the informed consent form.
- •Patients who are unsuitable for this study judged by clinicians.
研究组 & 干预措施
Selinexor combined with chidamide
R/R AML who are ineligible for intensive chemotherapy will receive selinexor in combination with chidamide, 28 days per cycle, Selinexor will be used as 40 or 60mg BIW for two weeks, and chidamide will be used as 10mg/d from day 1 to 28. Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.
干预措施: Selinexor (Drug)
Selinexor combined with chidamide
R/R AML who are ineligible for intensive chemotherapy will receive selinexor in combination with chidamide, 28 days per cycle, Selinexor will be used as 40 or 60mg BIW for two weeks, and chidamide will be used as 10mg/d from day 1 to 28. Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.
干预措施: Chidamide (Drug)
结局指标
主要结局
Number of Participants With ORR
时间窗: 28 days after study treatment
Defined as complete response (CR) + CR with incomplete blood count recovery (CRi) + morphologic leukemia-free state (MLFS) + partial response (PR).
次要结局
- Duration of Response (DOR)(2 years)
- Event-free survival (EFS)(Time from registration to event, max 3 years)
- Overall Survival (OS)(Time from registration to event, max 3 years)
- Number of Adverse Events (AE)(continuously from first administration of study drug untill 30 days after last study treatment. (approximately up to 1 year))